Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

Pfizer Inc. (NYSE: PFE) today reported financial results for third-quarter 2011. Third-quarter 2011 revenues were $17.2 billion, an increase of 7% compared with the year-ago quarter, which reflects operational growth of $247 million, or 1%, and the favorable impact of foreign exchange of $951 million, or 6%.

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has established a new Japanese vaccine research unit to be located in its Kasai R&D Center (Edogawa-ku, Tokyo).

Pfizer Inc. (NYSE: PFE) has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer.

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to September 30, 2011.

Sales of the Bayer Group rose by 1.0 percent in the third quarter to EUR 8,670 million (Q3 2010: EUR 8,581 million). The currency- and portfolio-adjusted (Fx & portfolio adj.) increase was 4.8 percent.

Bristol-Myers Squibb Company (NYSE: BMY) has announced double-digit net sales growth in a quarter highlighted by important new data on ELIQUIS ® for stroke prevention in patients with atrial fibrillation and continued investment in external innovation with several strategic transactions.